By delivering rapid, high-resolution, and reproducible data, the approach not only accelerates vaccine release but also enhances quality assurance and safety across important development and manufacturing workflows, supporting CEPI's 100 Days Mission.

This novel label-free technology detects subtle cellular changes from viral infection or gene expression, eliminating the need for reagents and lengthy endpoint assays.

With up to $195,811 in CEPI support, LumaCyte is partnering with IDT Biologika to deploy its Radiance® instrument and advance a reagent-free potency assay using Laser Force Cytology™ (LFC).

These assays are vital for confirming a vaccine’s ability to trigger an immune response and often rely on time-consuming cell culture and reagent-based methods that can delay development and release by days or even weeks.

Strengthening regionalised vaccine manufacturing is central to CEPI’s mission to ensure equitable access to vaccines, and we will continue to work with partners like RVMC to achieve this ambition.

Read full report: bit.ly/3JGVtCJ

The report highlights momentum & gaps:

🔵 Regional manufacturers supply only 29% of ASEAN, 25% of LAC, & 1% of Africa’s vaccine needs
🔵 Limited regulatory alignment constrains cross-border supply
🔵 Technology access and innovation capacity remain uneven across regions

Co-founded by CEPI, WEF, US NAM and other partners, RVMC aims to strengthen regional manufacturing and supply chains so that every region can access vaccines quickly and equitably in future outbreaks, helping to overcome a major barrier to access during the COVID-19 pandemic.

By reducing testing time from weeks to hours, this innovation could accelerate vaccine release, enhance quality control, and strengthen equitable access worldwide - advancing CEPI’s goal of developing vaccines at speed in support of the 100 Days Mission.

Their technology employs a lab technique that uses an electric field to move or separate particles and detect contamination in under 24 hours.

Developed through a WAHO-led regional working group, the Agenda identifies the most pressing policy and implementation priorities to ensure that Lassa vaccines, once developed, can be rapidly and equitably deployed across West Africa.

CEPI looks forward to working with the HLIP, the Joint Finance and Health Task Force, G20 members and global partners to advance these recommendations and strengthen global pandemic resilience.

Rapid surge financing for manufacturing scale-up and at-risk funding for low- and middle-income countries to procure medical countermeasures are essential to avoid repeating the inequities of the COVID-19 response.

We support recommendations to accelerate geographically diversified access to medical countermeasures.

Infectious disease threats—whether natural, accidental or deliberate—endanger health, prosperity and security, so the financial burden of protection should be shared across sectors, including security and defence.

CEPI welcomes the Panel’s call to increase domestic investment and non-ODA financing for pandemic prevention, preparedness and response.

Science and technology give us tools to prevent and contain outbreaks that were once unimaginable. But without sustained investment, the world will remain deeply vulnerable to the devastating health, economic and security impacts of future pandemics.

It’s a powerful endorsement of CEPI’s mission and a timely reminder that science, collaboration, and solidarity remain our strongest defences against future disease threats.